Literature DB >> 1377403

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

L A Kohlstaedt1, J Wang, J M Friedman, P A Rice, T A Steitz.   

Abstract

A 3.5 angstrom resolution electron density map of the HIV-1 reverse transcriptase heterodimer complexed with nevirapine, a drug with potential for treatment of AIDS, reveals an asymmetric dimer. The polymerase (pol) domain of the 66-kilodalton subunit has a large cleft analogous to that of the Klenow fragment of Escherichia coli DNA polymerase I. However, the 51-kilodalton subunit of identical sequence has no such cleft because the four subdomains of the pol domain occupy completely different relative positions. Two of the four pol subdomains appear to be structurally related to subdomains of the Klenow fragment, including one containing the catalytic site. The subdomain that appears likely to bind the template strand at the pol active site has a different structure in the two polymerases. Duplex A-form RNA-DNA hybrid can be model-built into the cleft that runs between the ribonuclease H and pol active sites. Nevirapine is almost completely buried in a pocket near but not overlapping with the pol active site. Residues whose mutation results in drug resistance have been approximately located.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1377403     DOI: 10.1126/science.1377403

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  603 in total

1.  Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.

Authors:  S Hannongbua; P Pungpo; J Limtrakul; P Wolschann
Journal:  J Comput Aided Mol Des       Date:  1999-11       Impact factor: 3.686

Review 2.  Archaeal DNA replication: identifying the pieces to solve a puzzle.

Authors:  I K Cann; Y Ishino
Journal:  Genetics       Date:  1999-08       Impact factor: 4.562

3.  A molecular-field-based similarity study of non-nucleoside HIV-1 reverse transcriptase inhibitors. 2. The relationship between alignment solutions obtained from conformationally rigid and flexible matching.

Authors:  J Mestres; D C Rohrer; G M Maggiora
Journal:  J Comput Aided Mol Des       Date:  2000-01       Impact factor: 3.686

4.  Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase.

Authors:  G Tachedjian; H E Aronson; S P Goff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Authors:  R A Smith; G J Klarmann; K M Stray; U K von Schwedler; R F Schinazi; B D Preston; T W North
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Phylogenetic relationships among group II intron ORFs.

Authors:  S Zimmerly; G Hausner
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

7.  Crystal structure of a thermostable type B DNA polymerase from Thermococcus gorgonarius.

Authors:  K P Hopfner; A Eichinger; R A Engh; F Laue; W Ankenbauer; R Huber; B Angerer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

8.  A molecular-field-based similarity study of non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  J Mestres; D C Rohrer; G M Maggiora
Journal:  J Comput Aided Mol Des       Date:  1999-01       Impact factor: 3.686

9.  Identification of conserved residues contributing to the activities of adenovirus DNA polymerase.

Authors:  H Liu; J H Naismith; R T Hay
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  Unique progressive cleavage mechanism of HIV reverse transcriptase RNase H.

Authors:  M Wisniewski; M Balakrishnan; C Palaniappan; P J Fay; R A Bambara
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.